Prospects to Translate the Biology of IL-33 and ST2 During Organ Transplantation into Therapeutics to Treat Graft-versus-host Disease

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2017 Feb 3

PMID 28149862

Citations 8

Authors

Ian C Scott

Kirsty F Houslay

E Suzanne Cohen

Affiliations

Soon will be listed here.

Citing Articles

Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?.

Alexoudi V, Gavriilaki E, Cheva A, Sakellari I, Papadopoulou S, Paraskevopoulos K Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543084 PMC: 10975293. DOI: 10.3390/ph17030298.

Stem Cell Therapy and Innate Lymphoid Cells.

Verma D, Verma M, Mishra R Stem Cells Int. 2022; 2022:3530520.

PMID: 35958032 PMC: 9363162. DOI: 10.1155/2022/3530520.

Computational Cosolvent Mapping Analysis Leads to Identify Salicylic Acid Analogs as Weak Inhibitors of ST2 and IL33 Binding.

Yuan X, Chinnaswamy K, Stuckey J, Yang C J Phys Chem B. 2022; 126(12):2394-2406.

PMID: 35294837 PMC: 9354565. DOI: 10.1021/acs.jpcb.2c00341.

Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.

Cavagnero K, Doherty T Ann Allergy Asthma Immunol. 2020; 126(2):135-142.

PMID: 32950684 PMC: 7855910. DOI: 10.1016/j.anai.2020.09.011.

A helminth-derived suppressor of ST2 blocks allergic responses.

Vacca F, Chauche C, Jamwal A, Hinchy E, Heieis G, Webster H Elife. 2020; 9.

PMID: 32420871 PMC: 7234810. DOI: 10.7554/eLife.54017.

References

Donovan C, Bourke J, Vlahos R . Targeting the IL-33/IL-13 Axis for Respiratory Viral Infections. Trends Pharmacol Sci. 2016; 37(4):252-261. DOI: 10.1016/j.tips.2016.01.004. View

Palmer G, Lipsky B, Smithgall M, Meininger D, Siu S, Talabot-Ayer D . The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008; 42(3):358-64. DOI: 10.1016/j.cyto.2008.03.008. View

Liu X, Hammel M, He Y, Tainer J, Jeng U, Zhang L . Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A. 2013; 110(37):14918-23. PMC: 3773798. DOI: 10.1073/pnas.1308651110. View

Byrne S, Beaugie C, OSullivan C, Leighton S, Halliday G . The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol. 2011; 179(1):211-22. PMC: 3123869. DOI: 10.1016/j.ajpath.2011.03.010. View

Lipsky B, Toy D, Swart D, Smithgall M, Smith D . Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol. 2012; 42(7):1863-9. DOI: 10.1002/eji.201142274. View

Ramaprakash H, Shibata T, Duffy K, Ismailoglu U, Bredernitz R, Moreira A . Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model. Am J Pathol. 2011; 179(1):104-15. PMC: 3123853. DOI: 10.1016/j.ajpath.2011.03.032. View

Fursov N, Johnston E, Duffy K, Cotty A, Petley T, Fisher J . Generation and characterization of rat anti-mouse ST2L monoclonal antibodies. Hybridoma (Larchmt). 2011; 30(2):153-62. DOI: 10.1089/hyb.2010.0100. View

Martin N, Martin M . Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016; 17(2):122-31. DOI: 10.1038/ni.3370. View

Percival-Alwyn J, England E, Kemp B, Rapley L, Davis N, McCarthy G . Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags". MAbs. 2014; 7(1):129-37. PMC: 4622073. DOI: 10.4161/19420862.2014.985489. View

10.

Turnquist H, Zhao Z, Rosborough B, Liu Q, Castellaneta A, Isse K . IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol. 2011; 187(9):4598-610. PMC: 3197898. DOI: 10.4049/jimmunol.1100519. View

11.

Qian L, Wu Z, Shen J . Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med. 2013; 17(8):966-75. PMC: 3780546. DOI: 10.1111/jcmm.12093. View

12.

Zhang J, Ramadan A, Griesenauer B, Li W, Turner M, Liu C . ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015; 7(308):308ra160. PMC: 4699312. DOI: 10.1126/scitranslmed.aab0166. View

13.

Matta B, Reichenbach D, Zhang X, Mathews L, Koehn B, Dwyer G . Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016; 128(3):427-39. PMC: 4957164. DOI: 10.1182/blood-2015-12-684142. View

14.

Cohen E, Scott I, Majithiya J, Rapley L, Kemp B, England E . Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. 2015; 6:8327. PMC: 4579851. DOI: 10.1038/ncomms9327. View

15.

Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert E . The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513(7519):564-568. PMC: 4339042. DOI: 10.1038/nature13577. View

16.

Kaur D, Gomez E, Doe C, Berair R, Woodman L, Saunders R . IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy. 2015; 70(5):556-67. PMC: 4418379. DOI: 10.1111/all.12593. View

17.

Lefrancais E, Cayrol C . Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw. 2013; 23(4):120-7. DOI: 10.1684/ecn.2012.0320. View

18.

Guabiraba R, Besnard A, Menezes G, Secher T, Jabir M, Amaral S . IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol. 2014; 7(5):1079-93. PMC: 4077764. DOI: 10.1038/mi.2013.124. View

19.

Liew F, Girard J, Turnquist H . Interleukin-33 in health and disease. Nat Rev Immunol. 2016; 16(11):676-689. DOI: 10.1038/nri.2016.95. View

20.

Vander Lugt M, Braun T, Hanash S, Ritz J, Ho V, Antin J . ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013; 369(6):529-39. PMC: 3943357. DOI: 10.1056/NEJMoa1213299. View